Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
囊泡 肿瘤
/
细胞凋亡
外泌体 帕金森与阿尔茨海默症 肿瘤生长增殖和凋亡 Notch
/
p53
凋亡
/ PRIMA-1

PRIMA-1 {[allProObj[0].p_purity_real_show]}

货号：A755385 同义名： NSC-281668

PRIMA-1 is a mutant p53 reactivator. It induces apoptosis and inhibits growth of human tumors with mutant p53.

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
PRIMA-1 化学结构 CAS号：5608-24-2
PRIMA-1 化学结构
CAS号：5608-24-2
PRIMA-1 3D分子结构
CAS号：5608-24-2
PRIMA-1 化学结构 CAS号：5608-24-2
PRIMA-1 3D分子结构 CAS号：5608-24-2
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} 		{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

PRIMA-1 纯度/质量文件 产品仅供科研

货号：A755385 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]
• JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]
• BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]
• J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]
• PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]
更多 >
产品名称 p53 ↓ 其他靶点 纯度
Pifithrin-μ ✔ 99%+
Pifithrin-α HBr ✔ 98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

PRIMA-1 生物活性

描述 The tumor suppressor p53 is a crucial mediator of cell cycle arrest and apoptosis in response to various forms of cellular stress, including DNA damage, oncogene activation, and hypoxia, and at least 50% of human tumors carry mutations in p53. PRIMA-1 is a mutant p53 reactivator. PRIMA-1 induced apoptosis in p53 mutant pancreatic cancer cells by promoting the re-activation of p53 and inducing proapoptotic signaling pathways[3]. Esophageal squamous cell carcinoma cell lines with different TP53 mutation status treated with PRIMA-1(25 and 50 μM) for 24-48 hour showed significant increased percentage of Annexin V-positive cells and PRIMA-1 upregulated the pro-apoptotic protein Noxa in a dose-dependent manner[4]. PRIMA-1 treatment at 25 μM in JJN3 cells could partially rescue tunicamycin-induced-XBP1s and had no significant effect on ATF6[5]. PRIMA-1 treatment at 200 μM in both MDA-MB-231 cancer cells knocked-down for mutant p53 and MDA-MB-231 cancer cells carrying mutant p53 induced autophagy[6].
作用机制 PRIMA-1 reactivates mutant p53 by forming adducts with thiols in mutant p53.

PRIMA-1 动物研究

Dose Mice: 20 mg/kg, 100 mg/kg[3] (i.p.)
Administration i.p.

PRIMA-1 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02999893 Oesophageal Carcinoma Phase 1 Phase 2 Recruiting April 30, 2023 Australia, Victoria ... 展开 >> Monash Medical Centre Recruiting Clayton, Victoria, Australia, 3000 Contact: Benjamin Markman          Principal Investigator: Benjamin Markman, MBBS, FRACP          Austin Health Not yet recruiting Heidelberg, Victoria, Australia, 3000 Contact: Niall Tebbutt          Principal Investigator: Niall Tebbutt, MBBS, FRACP          Peter MacCallum Cancer Centre Recruiting Melbourne, Victoria, Australia, 3002 Contact: Lara Lipton, MSc       lara.lipton@petermac.org    Principal Investigator: Lara Lipton, MBBS, FRACP          Sub-Investigator: Michael Michael, MBBS, FRACP          Alfred Hospital Not yet recruiting Prahran, Victoria, Australia, 3000 Contact: Andrew Haydon          Principal Investigator: Andrew Haydon, MBBS, FRACP          Sunshine Hospital Western Health Not yet recruiting Sunshine, Victoria, Australia, 3000 Contact: Lara Lipton       lara.lipton@petermac.org    Principal Investigator: Lara Lipton, MBBS, FRACP 收起 <<
NCT03588078 Myelodysplastic Syndrome With ... 展开 >>Gene Mutation Acute Myeloid Leukemia With Gene Mutations Myeloproliferative Neoplasm Chronic Myelomonocytic Leukemia 收起 << Phase 1 Phase 2 Recruiting May 15, 2021 France ... 展开 >> Hôpital Archet 1 Recruiting Nice, France, 06200 Contact: Thomas CLUZEAU, Prof    33492035844    cluzeau.t@chu-nice.fr    Principal Investigator: Pierre Fenaux, Pr          Hôpital Saint Louis - Hématologie Séniors Recruiting Paris, France, 75010 Contact: Pierre Fenaux, MD    033170207022    pierre.fenaux@sls.aphp.fr    Principal Investigator: Pierre Fenaux, MD 收起 <<
NCT03072043 Myelodysplastic Syndrome ... 展开 >> Acute Myeloid Leukemia Myeloproliferative Neoplasm Chronic Myelomonocytic Leukemia 收起 << Phase 1 Phase 2 Recruiting May 2021 United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center and Research Institute Recruiting Tampa, Florida, United States, 33612 Contact: Lisa Nardelli    813-745-4731    lisa.nardelli@moffitt.org    Contact: David Sallman, M.D.    813-745-4673    david.sallman@moffit.org    Principal Investigator: David Sallman, M.D.          Sub-Investigator: Rami Komrokji, M.D.          Sub-Investigator: Jeffrey Lancet, M.D.          Sub-Investigator: Alan List, M.D.          Sub-Investigator: Kathy McGraw, Ph.D.          Sub-Investigator: Eric Padron, M.D.          Sub-Investigator: Kendra Sweet, M.D.          Sub-Investigator: Ling Zhang, M.D.          Sub-Investigator: Rachid Baz, M.D.          United States, Maryland The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Recruiting Baltimore, Maryland, United States, 21231 Contact: Amy DeZern, M.D.    410-502-7208    adezern1@jhmi.edu    Principal Investigator: Amy DeZern, M.D.          United States, Massachusetts Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: David Steensma, M.D.    617-632-5202    dsteensma@partners.org    Principal Investigator: David Steensma, M.D.          United States, New York Weill Medical College of Cornell University Recruiting New York, New York, United States, 10065 Contact: Finola Goudy    212-746-4447    fig4001@med.cornell.edu    Principal Investigator: Gail Roboz, MD          Sub-Investigator: Ellen Ritchie, MD          Sub-Investigator: Sangmin Lee, MD          Sub-Investigator: Pinkal Desai, MD          Sub-Investigator: Michael Samuel, MD          Sub-Investigator: Jeffrey Ball, MD          Sub-Investigator: Sandra Allen-Bard, PA          Sub-Investigator: Natalie Tafel, PA          United States, Ohio Cleveland Clinic Taussig Cancer Center Recruiting Cleveland, Ohio, United States, 44195 Contact: Mikkael A. Sekeres, M.D.    216-445-9353    sekerem@ccf.org    Principal Investigator: Mikkael A. Sekeres, M.D.          United States, Texas University of Texas M.D. Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Heather Schneider, RN    713-792-4478    HNSchneider@mdanderson.or    Principal Investigator: Guillermo Garcia-Manero, MD 收起 <<

PRIMA-1 参考文献

[1]Izetti P, Hautefeuille A, et al. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines. Invest New Drugs. 2014 Oct;32(5):783-94.

[2]Lambert JM, Gorzov P, et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell. 2009 May 5;15(5):376-88.

[3]Izetti P, Hautefeuille A, Abujamra AL, de Farias CB, Giacomazzi J, Alemar B, Lenz G, Roesler R, Schwartsmann G, Osvaldt AB, Hainaut P, Ashton-Prolla P. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines. Invest New Drugs. 2014 Oct;32(5):783-94. doi: 10.1007/s10637-014-0090-9. Epub 2014 May 20. PMID: 24838627.

[4]Furukawa H, Makino T, Yamasaki M, Tanaka K, Miyazaki Y, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M, Doki Y. PRIMA-1 induces p53-mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation. Cancer Sci. 2018 Feb;109(2):412-421. doi: 10.1111/cas.13454. Epub 2017 Dec 28. PMID: 29168598; PMCID: PMC5797815.

[5]Teoh PJ, Bi C, Sintosebastian C, Tay LS, Fonseca R, Chng WJ. PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation. Oncotarget. 2016 Sep 20;7(38):61806-61819. doi: 10.18632/oncotarget.11241. PMID: 27533450; PMCID: PMC5308692.

[6]Russo D, Ottaggio L, Foggetti G, Masini M, Masiello P, Fronza G, Menichini P. PRIMA-1 induces autophagy in cancer cells carrying mutant or wild type p53. Biochim Biophys Acta. 2013 Aug;1833(8):1904-13. doi: 10.1016/j.bbamcr.2013.03.020. Epub 2013 Mar 29. PMID: 23545415.

PRIMA-1 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

5.40mL

1.08mL

0.54mL

26.99mL

5.40mL

2.70mL

53.99mL

10.80mL

5.40mL

PRIMA-1 技术信息

CAS号5608-24-2
分子式C9H15NO3
分子量 185.22
别名 NSC-281668
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Inert atmosphere,2-8°C
溶解度

DMSO: 50 mg/mL(269.95 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 100 mg/mL(539.9 mM)，配合低频超声助溶
动物实验配方

Tags: PRIMA-1 | 5608-24-2 | NSC-281668 | PRIMA1 | PRIMA 1 | NSC281668 | NSC 281668 | Mutant p53 ReActivator | Autophagy | Apoptosis | Autophagy | MDM-2/p53 | Ferroptosis | Apoptosis | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | PRIMA-1 纯度/质量文件 | PRIMA-1 亚型比较 | PRIMA-1 生物活性 | PRIMA-1 动物研究 | PRIMA-1 临床数据 | PRIMA-1 参考文献 | PRIMA-1 实验方案 | PRIMA-1 技术信息

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 Ambeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z